Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol is a blinded randomized controlled study of the effects of BB-12 with LGG at different doses in 70 healthy children with autism spectrum disorders at lower and higher doses over an 56-day period and a 28- day observation period. The study is being conducted in order to assess safety and tolerability of the probiotic (BB-12 with LGG) at 2 different doses of BB-12 with LGG. Identifying effects on behaviors in healthy children with ASD using SRS-2 and ABC, GI symptoms using GI symptom severity index, and relevant biomarkers of inflammation, microbiota, and metabolites. Primary testing and procedures will be conducted at the University of Texas Health Science Center at Houston and Memorial Hermann.

Biomarker identification includes Integrative analysis of plasma metabolome and stool microbiota will be conducted with the collaboration of Dr. Ruth Ann Luna and Dr. Jim Versalovic at Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology \& Microbiology of Baylor College of Medicine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Vivomixx on Behaviour and Gut Function in Autism Spectrum Disorder

NCT03369431

Autism Spectrum Disorder

COMPLETED NA

Probiotic in Autism

NCT04939974

Autism Spectrum Disorder

UNKNOWN NA

Randomized Double-blind Clinical Trial With L.Reuteri Supplementation in Children With Autism Spectrum Disorder

NCT04293783

Autism Spectrum Disorder

COMPLETED NA

Assessing the Impact of Probiotic Supplementation in Children Diagnosed With Autism Spectrum Disorder: the PROBI-O-TISM Study

NCT06906068

Autism Spectrum Disorder

NOT_YET_RECRUITING NA

Prebiotic Intervention for Autism Spectrum Disorders

NCT02720900

Autism

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder Gastrointestinal Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

After psychological screening, the subjects will be randomize children to one of 3 groups. The total number of subject to be enrolled will be 70 healthy children with confirmed ASD status, randomizing each child to placebo (maltodextrin), low daily dose (1 billion cfu's), and higher daily dose (10 billion cfu's) of BB-12+LGG once daily at 1:2:2 ratio. Data will be combined with 30 patients obtained from two funding sources: Texas (THECB) and U.T. pilot project. The data will be combined and an identical design of the placebo and 1 billion cfu dose arms.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

The head statistician and study pharmacist will be aware of randomization scheme. The investigators will use an adaptive minimization program for randomization that balances the 3 study arms with respect to distributions of sex and age (4-10 vs. 11-16 y.o.). Patients will be randomized to placebo, 1 billion CFU, and 10 billion CFU study arms at a ratio of 1:2:2. (Currently marketed over-the-counter probiotics typically contain 0.1-50 billion CFUs per dose.) The performance of our covariate adaptive randomization algorithm will be verified through simulation studies before implementation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BB-12 with LGG (Lower Dose)

BB-12 with LGG (Multistrain probiotic; lower dose): 1 billion CFUs

Group Type ACTIVE_COMPARATOR

BB-12 with LGG (Lower Dose)

Intervention Type DRUG

BB-12 with LGG - Lower Dose (1 billion CFUs)

Placebo

Maltodextrin

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Maltodextrin

BB-12 with LGG (Higher Dose)

BB-12 with LGG (Multistrain probiotic: higher dose): 10 billion CFUs

Group Type ACTIVE_COMPARATOR

BB-12 with LGG (Higher Dose)

Intervention Type DRUG

BB-12 with LGG - Higher Dose (10 billion CFUs)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BB-12 with LGG (Higher Dose)

BB-12 with LGG - Higher Dose (10 billion CFUs)

Intervention Type DRUG

Placebo

Maltodextrin

Intervention Type DRUG

BB-12 with LGG (Lower Dose)

BB-12 with LGG - Lower Dose (1 billion CFUs)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Probiotic Maltodextrin Probiotic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy children with autism spectrum disorders (4 - 16 years old) and gastrointestinal symptoms, based on the GI Severity Index, with no other recognized illness will be enrolled in this study. There will be no selection on the basis of age, race, or gender. Although the investigators anticipate the majority of subjects will be male and/or pre-pubertal, in females of childbearing potential, a pregnancy test (urine) will be performed on females participating (at each visit).

Exclusion Criteria

* Pregnancy or breastfeeding
* Subjects taking immunosuppressive medications, including oral corticosteroids
* A History of Positive result of HIV, Hepatitis B, and/or Hepatitis C test
* Abnormal lab test results (Section 5.2)
* Gastrointestinal diseases such as celiac disease, inflammatory bowel disease
* Subjects with an allergy to antibiotics
* Presence of fever or a pre-existing adverse event monitored in the study
* Use of probiotics in the last 30 days
* Acute diarrheal illness within the past 30 days
* Recent (within 2 weeks) or current use of oral antibiotics /anti-fungals Current use of oral laxatives
* Subjects with implanted prosthetic devices including prosthetic heart valves
* The investigators will require that subject not take any other probiotic-containing products, including yogurt supplemented with probiotics during the study period.

Minimum Eligible Age

4 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes